A recent report published by Infinium Global Research on multiple myeloma drugs market provides an in-depth analysis of segments and sub-segments in global as well as regional multiple myeloma drugs market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional multiple myeloma drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global multiple myeloma drugs market. According to the report the global Multiple Myeloma drugs market is projected to grow at a CAGR of 9.2% over the forecast period of 2018-2024.
Multiple Myeloma is a type of cancer that is formed by malignant plasma cells. The normal plasma cells are mostly found in bone marrow and are thus an important part of the immune system. Multiple myelomas cause cancer cells to accumulate in the bone marrow, wherein they crowd out healthy blood cells. Rather than producing helpful antibodies, the cancer cells produce abnormal proteins that can cause complications.
Multiple Myeloma Drugs market was worth around XX million in 2017 and is anticipated to reach around XX million around 2024, in terms of revenue. Growing cases of plasma cancer across the globe due to exposure to harmful radiations or chemical, immune disorders or family history of the disease. Increased utilization of stem cell transplants and other new therapies. Also, the development of novel drugs coupled with the use of imaging technologies for disease assessment to augment the growth for the multiple myeloma drugs. These aforementioned factors are primarily responsible to drive the multiple myeloma drugs market. However, high treatment cost affects the multiple myeloma market, According to a study, there is a considerable population that is still not able to afford multiple myeloma cancer treatment. The development of new drugs and investment in research and development projects by government and non-government organizations is further expected to boost market growth.
Among the regions, North America accounted for the dominant share in 2017. The U.S primarily drives the North America multiple myeloma market, on account of the presence of major multiple myeloma drugs manufacturing companies and their efforts in developing novel products to treat multiple myeloma cancer. Furthermore, factors such as increased healthcare infrastructure and improved healthcare reimbursement policies too are responsible to augment multiple myeloma drug market. Asia Pacific is expected to grow at the highest CAGR during the forecast period, 2018-2024 on account of the huge population base, that in turn increases the chances of more number of people being affected with multiple myeloma market and increased government initiatives to assist people affected with cancer disease.
The report on global Multiple Myeloma Drugs market covers segments such as drug type and distribution channel. On the basis of drug type the global multiple myeloma drugs market is categorized into immunomodulating agents, proteasome inhibitors, histone deacetylase (HDAC) inhibitors, monoclonal antibodies, and others. On the basis of distribution channel the global multiple myeloma drugs market is categorized into retail pharmacy, hospital pharmacy, and online channel.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2026. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global multiple myeloma drugs market such as Onyx Pharmaceuticals, Bristol-Myers Squibb, Novartis, Pfizer, Johnson and Johnson, Celgene Corporation and Takeda Pharmaceuticals.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global Multiple Myeloma Drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of Multiple Myeloma Drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the Multiple Myeloma Drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the Multiple Myeloma Drugs market to understand the present and future trends in this market and formulate their strategies accordingly.